A Pilot Study of BMS-512148 in Subjects with Type 2 Diabetes

Study identifier:MB102-009

ClinicalTrials.gov identifier:NCT00357370

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Pilot Study of the Efficacy and Safety of BMS-512148 on Glycemic Control in Subjects with Type 2 Diabetes Treated Aggressively but not Controlled on Combination Antihyperglycemic Therapy with Metformin and/or Thiazolidinedione (TZD) and Insulin.

Medical condition

Type 2 Diabetes

Phase

Phase 2/3

Healthy volunteers

No

Study drug

Dapagliflozin, Placebo

Sex

All

Actual Enrollment

163

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Oct 2006
Primary Completion Date: 01 Mar 2008
Study Completion Date: 01 Mar 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2017 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Bristol-Myers Squibb

Inclusion and exclusion criteria